0
A phase 2, open-label, single-arm clinical trial of the safety and efficacy of the JAK1/3 inhibitor tofacitinib in Down syndrome. (linkinghub.elsevier.com)
Authors:
Rachubinski AL
… Espinosa JM
Journal:
Cell Reports Medicine
Published:
2026-11-17
DOI:
https://doi.org/10.1016/j.xcrm.2026.103138
Comments
Login to comment.
No comments yet. Be the first!